Role of Restaging Transurethral Resection for T1 Non–muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis

Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection

“…A number of quality issues, some potentially linked to the experience of the surgeon, indeed suggest that the initial TURBT may be inadequate in a high percent of these patients, with residual tumor rates varying between 33% and 76% for all the cases, achieving 27-72% and 33-78% for Ta and T1 tumors, respectively. Even more strikingly, underestimation of tumor depth invasion at first TURBT has been evidenced in up to 7-30% of cases, increasing up to 45-51% in those with HG-T1 tumors undergoing RC or in those where no muscle was detected in the specimen after initial resection [20,21].…”

Surgical checklist impact on recurrence‐free survival of patients with non‐muscle‐invasive bladder cancer undergoing transurethral resection of bladder tumour

“…Thus, the quality of an initial resection plays a significant role in the risk of intravesical recurrence. Numerous studies have reported residual tumour at re‐TURBT in 30% of patients at the prior resection site and 70% with tumour elsewhere in the bladder . Tumour persistence and early recurrence may be attributed to missed tumours, an incomplete resection, re‐implantation of tumour cells after resection, and de novo tumour formation .…”

Repeat transurethral resection is still an essential tool in treating non-muscle invasive bladder cancer: the Western Australian experience

“…In patients with extensive high-grade stage T1 disease, the rate of under-staging can be as high as 67.9% [4]. In a recent meta-analysis, the pooled prevalence rate of upstaging to stage T2 disease at repeat TUR was 11% (95% CI 0.06-0.18) [9]. In the subgroup with muscle detected at initial TUR, the pooled prevalence rate of upstaging to stage T2 disease at repeat TUR was 10% (95% CI 0.06-0.14) [9].…”

“…In a recent meta-analysis, the pooled prevalence rate of upstaging to stage T2 disease at repeat TUR was 11% (95% CI 0.06-0.18) [9]. In the subgroup with muscle detected at initial TUR, the pooled prevalence rate of upstaging to stage T2 disease at repeat TUR was 10% (95% CI 0.06-0.14) [9]. In comparison, our study demonstrated a low rate of upstaging to stage T2 disease (3.0%) at repeat TUR but a significant rate of residual disease (41.8%).…”